BACKGROUND Precocious puberty (PP) is defined as the appearance of secondary sex characteristic at an age <8 years in girls and <9 years in boys, or menarche <9 years in girls. OBJECTIVE To determine the etiologies and clinical characteristics of children presenting with PP. SUBJECTS AND METHOD The medical records of 307 children (292 girls, 15 boys) with PP (1995-2009) were reviewed. RES...

BACKGROUND The genetic background of idiopathic central precocious puberty (ICPP) is not well understood, and is thought to arise from the effect of multiple genes. Familial ICPP have been reported suggesting the existence of monogenic causes of ICPP. The neurokinin B (NKB) system has recently been implicated in the regulation of the human reproductive axis. In humans, NKB and its receptor are ...

BACKGROUND The mechanism that initiates the onset of puberty is largely unknown but the age of onset is mainly under genetic control and influenced by environmental factors including nutrition. The coexistence in the same family of central precocious puberty and advanced puberty, both representing early puberty, suggests that they may represent a clinical spectrum of the same trait due to early...

Macroprolactinemia was recognized more than a decade ago as a cause of hyperprolactinemia and the prevalence of macroprolactinemia is thought to be 10%-26% of patients with hyperprolactinemia. However, there are few published reports about macroprolactinemia in childhood. We report a 7-year-and-1-month-old girl with hyperprolactinemia due to macroprolactinemia with the complication of transient...

In boys, central precocious puberty (CPP) is the appearance of secondary sex characteristics driven by pituitary gonadotropin secretion before the age of 9 years. In the last years, relevant improvements in the treatment of CPP have been achieved. Because CPP is rare in boys, the majority of papers on this issue focus on girls and do not address specific features of male patients regarding end ...

BACKGROUND Depot preparations of gonadotropin-releasing hormone agonists (GnRHa) are the gold standard drugs for the treatment of central precocious puberty. A concern about these drugs is obesity. OBJECTIVES This study aimed to investigate the effect of gonadotropin-releasing hormone agonists (GnRHa) therapy on body mass index (BMI) in girls with central precocious puberty (CPP). PATIENTS ...

PURPOSE A gonadotropin-releasing hormone stimulation test (GnRHST) is the gold standard in diagnosing central precocious puberty (CPP). The aim of this study was to investigate the diagnostic accuracy of basal gonadotropin levels for girls with suspected precocious puberty and to evaluate the factors affecting positive results of the GnRHST. METHODS Korean girls with early pubertal developmen...

Methods Serum levels of E2, NT proCNP, insulin like growth factor 1(IGF1), NMID Osteocalcin(OC) and carboxy-terminal cross-linking telopeptide of type I collagen (b-CrossLaps) were measured in healthy 57 girls at different pubertal stages, and in 13 girls with ICPP at the beginning and the end of 6 month and 12 month of GnRHa treatment. Height velocities of the 13 ICPP girls in each 6 months be...

UNLABELLED Some adolescents with a history of idiopathic central precocious puberty (ICPP) develop hyperandrogenism. HYPOTHESIS Luteinizing hormone (LH) hypersecretion could be a common mechanism underlying ICPP and polycystic ovary syndrome. AIM To explore the GnRH-LH axis in those patients. DESIGN To compare overnight LH secretion in 7 healthy adolescents (CG) with that in patients with...

The adult height of children with early onset puberty is limited by the premature maturation of hypothalamic-pituitary-gonadal axis. To evaluate the effects of gonadotropin-releasing hormone analog (GnRHa) treatment on the final height (FH) and bone maturation rate (BMR) in girls with early puberty (EP) or idiopathic central precocious puberty (ICPP), we examined data from girls who were diagno...